TECH
$51.06
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
Intraday
Recent News
Should You Continue to Hold Bio-Techne Stock in Your Portfolio?
TECH expands via acquisitions and global growth, but biotech funding softness, U.S. academic spending pressure and competition cloud near-term outlook.
Assessing Bio‑Techne (TECH) Valuation After Institutional Buying Earnings Beat And New AI Drug Discovery Push
Bio-Techne (TECH) is back in focus after institutional investors such as Jefferies Financial Group and Madison Investments increased their exposure, alongside earnings that topped expectations and fresh AI collaborations in drug discovery. See our latest analysis for Bio-Techne. Despite upbeat earnings and fresh AI partnerships, Bio-Techne’s recent share price performance has been weak, with a 30 day share price return of a 19.9% decline and a 1 year total shareholder return of a 17.7% loss...
Is Bio-Techne Stock a Buy, Sell, or Hold After a Wealth Manager Dumps Its Entire Stake?
Bio-Techne develops specialized reagents and diagnostic solutions for global research and clinical markets in the life sciences sector.
3 Cash-Producing Stocks with Open Questions
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
What Makes Bio-Techne Corporation (TECH) a Good Investment?
Madison Investments, an investment advisor, released its fourth-quarter 2025 investor letter for “Madison Mid Cap Fund”. A copy of the letter can be downloaded here. The Russell Midcap Index ended an incredibly successful three-year run with a full-year return of 10.6%, amounting to an annual increase of more than 14%. The market favored more volatile and […]